BACKGROUND: (131) I-Metaiodobenzylguanidine ((131) I-MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and (131) I-MIBG is concentrated in the liver after (131) I-MIBG therapy. The aim of our study was to analyze the effects of (131) I-MIBG therapy on thyroid and liver function. PROCEDURE: Pre- and post-therapy thyroid and liver functions were reviewed in a total of 194 neuroblastoma patients treated with (131) I-MIBG therapy. The cumulative incidence over time was estimated for both thyroid and liver toxicities. The relationship to cumulative dose/kg, number of treatments, time from treatment to follow-up, sex, and patient age was examined. RESULTS: In patients who presented with Grade 0 or 1 thyroid toxicity at baseline, 12 ± 4% experienced onset of or worsening to Grade 2 hypothyroidism and one patient developed Grade 2 hyperthyroidism by 2 years after (131) I-MIBG therapy. At 2 years post-(131) I-MIBG therapy, 76 ± 4% patients experienced onset or worsening of hepatic toxicity to any grade, and 23 ± 5% experienced onset of or worsening to Grade 3 or 4 liver toxicity. Liver toxicity was usually transient asymptomatic transaminase elevation, frequently confounded by disease progression and other therapies. CONCLUSION: The prophylactic regimen of potassium iodide and potassium perchlorate with (131) I-MIBG therapy resulted in a low rate of significant hypothyroidism. Liver abnormalities following (131) I-MIBG therapy were primarily reversible and did not result in late toxicity. (131) I-MIBG therapy is a promising treatment for children with relapsed neuroblastoma with a relatively low rate of symptomatic thyroid or hepatic dysfunction.
BACKGROUND: (131) I-Metaiodobenzylguanidine ((131) I-MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and (131) I-MIBG is concentrated in the liver after (131) I-MIBG therapy. The aim of our study was to analyze the effects of (131) I-MIBG therapy on thyroid and liver function. PROCEDURE: Pre- and post-therapy thyroid and liver functions were reviewed in a total of 194 neuroblastomapatients treated with (131) I-MIBG therapy. The cumulative incidence over time was estimated for both thyroid and liver toxicities. The relationship to cumulative dose/kg, number of treatments, time from treatment to follow-up, sex, and patient age was examined. RESULTS: In patients who presented with Grade 0 or 1 thyroid toxicity at baseline, 12 ± 4% experienced onset of or worsening to Grade 2 hypothyroidism and one patient developed Grade 2 hyperthyroidism by 2 years after (131) I-MIBG therapy. At 2 years post-(131) I-MIBG therapy, 76 ± 4% patients experienced onset or worsening of hepatic toxicity to any grade, and 23 ± 5% experienced onset of or worsening to Grade 3 or 4 liver toxicity. Liver toxicity was usually transient asymptomatic transaminase elevation, frequently confounded by disease progression and other therapies. CONCLUSION: The prophylactic regimen of potassium iodide and potassium perchlorate with (131) I-MIBG therapy resulted in a low rate of significant hypothyroidism. Liver abnormalities following (131) I-MIBG therapy were primarily reversible and did not result in late toxicity. (131) I-MIBG therapy is a promising treatment for children with relapsed neuroblastoma with a relatively low rate of symptomatic thyroid or hepatic dysfunction.
Authors: Mark N Gaze; Yen-Ch'ing Chang; Glenn D Flux; Rob J Mairs; Frank H Saran; Simon T Meller Journal: Cancer Biother Radiopharm Date: 2005-04 Impact factor: 3.099
Authors: Katherine K Matthay; Jessica C Tan; Judith G Villablanca; Gregory A Yanik; Janet Veatch; Benjamin Franc; Eilish Twomey; Biljana Horn; C Patrick Reynolds; Susan Groshen; Robert C Seeger; John M Maris Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: K K Matthay; K DeSantes; B Hasegawa; J Huberty; R S Hattner; A Ablin; C P Reynolds; R C Seeger; V K Weinberg; D Price Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: T Klingebiel; P Bader; R Bares; J Beck; B Hero; H Jürgens; P Lang; D Niethammer; B Rath; R Handgretinger Journal: Eur J Cancer Date: 1998-08 Impact factor: 9.162
Authors: R J Hutchinson; J C Sisson; J S Miser; K R Zasadny; D P Normolle; B L Shulkin; I R Francis; D M Wieland; B Shapiro Journal: J Nucl Biol Med Date: 1991 Oct-Dec
Authors: Swati S More; Melissa Itsara; Xiaodong Yang; Ethan G Geier; Michelle K Tadano; Youngho Seo; Henry F Vanbrocklin; William A Weiss; Sabine Mueller; Daphne A Haas-Kogan; Steven G Dubois; Katherine K Matthay; Kathleen M Giacomini Journal: Clin Cancer Res Date: 2011-03-18 Impact factor: 12.531
Authors: S C Clement; R R van Rijn; B L F van Eck-Smit; A S P van Trotsenburg; H N Caron; G A M Tytgat; H M van Santen Journal: Eur J Nucl Med Mol Imaging Date: 2014-12-16 Impact factor: 9.236
Authors: Lorraine R Reitzel; Nga Nguyen; Yumei Cao; Jennifer Irvin Vidrine; Patricia Daza; Patricia Dolan Mullen; Mary M Velasquez; Yisheng Li; Paul M Cinciripini; Ludmila Cofta-Woerpel; David W Wetter Journal: Nicotine Tob Res Date: 2011-05-26 Impact factor: 4.244
Authors: Megan Trieu; Steven G DuBois; Elizabeth Pon; Lorenzo Nardo; Randall A Hawkins; Araz Marachelian; Clare J Twist; Julie R Park; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2015-10-27 Impact factor: 3.167